| LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120014940 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT AND NON-MALIGNANT GAMMOPATHIES - The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either. | 01-19-2012 |
| 20110311539 | DIAGNOSIS AND TREATMENT OF CANCER USING CANCER-TESTIS ANTIGENS - The invention relates to CT polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigens CT1.1 (CTSP-5), CT1.11 (CTSP-6), CT1.19 (CTSP-7), CT1.26 (CTSP-8), and CT1.29 (CTSP-9). | 12-22-2011 |
| 20110293658 | USE OF INKT OR TLR AGONISTS FOR PROTECTING AGAINST OR TREATING A DISEASE SUCH AS ACUTE INFECTION OR CANCER - A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a combination thereof. | 12-01-2011 |
| 20110293648 | SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4 | 12-01-2011 |
| 20110281289 | QUANTIFICATION OF ENZYME ACTIVITY BY MASS SPECTROMETRY USING IMMOBILIZED SUBSTRATES - The disclosure relates to methods of analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Immobilized substrates are employed. Purified enzymes and enzymes from crude cell lysates can be analyzed using the disclosed methods. | 11-17-2011 |
| 20110159017 | TRYTOPHAN CATABOLISM IN CANCER TREATMENT AND DIAGNOSIS - The unexpected expression of tryptophan 2,3-dioxygenase (TDO2) in cancer cells and tumors has been established. Methods for diagnosing cancer based on the expression of TDO2 are provided, as are methods for treating cancer and inhibiting the growth of cancer cells by inhibiting TDO2, as well as pharmaceutical compositions. | 06-30-2011 |
| 20110144186 | SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4 | 06-16-2011 |
| 20110091967 | SSX-4 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-4 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4 | 04-21-2011 |
| 20110082185 | CANCER-TESTIS GENE SILENCING AGENTS AND USES THEREOF - The invention relates to methods, formulations and kits useful for inhibiting cancer cell viability, invasion, or migration. | 04-07-2011 |
| 20100322949 | METHODS FOR DIAGNOSING AND TREATING ASTROCYTOMAS - The invention relates to the identification of astrocytoma markers, astrocytoma stem cells and markers of such stem cells, and diagnostic, prognostic and therapeutic methods based on an understanding of the markers and cells. | 12-23-2010 |
| 20100221254 | Methods and Compositions for PDGF-C Activation and Inhibition - Methods for inhibiting angiogenesis comprising administering tissue-plasminogen activator (tPA) inhibitors, and pharmaceutical compositions suitable for the methods comprising the tPA inhibitors. Also provided are methods for stimulating angiogenesis comprising administering tPA to a patient in need thereof, and pharmaceutical compositions comprising an effective amount of tPA for the methods of stimulation. The present invention discloses that tPA is a specific PDGF-C activating protease, and that the CUB-domains in PDGF-CC directly interact with the protease, are required for efficient proteolysis, and released CUB-domains are tPA inhibitors. Preferably, the method and compositions of the present invention are used for simultaneously stimulating, or simultaneously inhibiting, thrombolysis and angiogenesis. | 09-02-2010 |
| 20100172910 | HUMAN SARCOMA-ASSOCIATED ANTIGENS - The invention relates to sarcoma-associated antigens and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof associated with sarcoma in methods and compositions for the diagnosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, NY-SAR-35. | 07-08-2010 |
| 20100143359 | EXPRESSION OF FOXP3 BY CANCER CELLS - The present invention relates to the treatment, diagnosis, and prophylaxis of cancer based on the expression of foxp3. | 06-10-2010 |
| 20090274716 | LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS - The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product. | 11-05-2009 |
| 20090238824 | BREAST, GASTRIC AND PROSTATE CANCER ASSOCIATED ANTIGENS AND USES THEREFOR - Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast, gastric and prostate cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens. | 09-24-2009 |
| 20090209034 | TUMOUR REJECTION ANTIGENS - Polypeptides comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1. | 08-20-2009 |
| 20090136446 | INDUCTION OF REGULATORY T CELL-RESISTANT HELPER CD4+ T CELLS - The invention relates to stimulation of immune responses against antigen(s) and overcoming regulatory T cell suppression of such immune responses against antigen(s). | 05-28-2009 |
| 20090099063 | SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating to the peptides. The peptides stimulate the activity and proliferation of CD4 | 04-16-2009 |
